两种大麻二酚油产品对自我报告的压力缓解的影响:一项准实验研究。

Q1 Medicine
Medical Cannabis and Cannabinoids Pub Date : 2023-11-06 eCollection Date: 2023-01-01 DOI:10.1159/000531886
Mohammed Faraj, Tyler Dautrich, Leslie Lundahl, Hilary Marusak
{"title":"两种大麻二酚油产品对自我报告的压力缓解的影响:一项准实验研究。","authors":"Mohammed Faraj, Tyler Dautrich, Leslie Lundahl, Hilary Marusak","doi":"10.1159/000531886","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Estimated rates of past-month cannabidiol (CBD) use in the general public are 13-26% and emerging research examines CBD as a potential adjunct treatment for several medical conditions, including stress-related disorders (e.g., depression, anxiety, and chronic pain). However, little is known about the effects of different CBD products on self-reported stress. The present study compared the effects of two delta-9-tetrahydrocannabinol (THC)-free CBD tincture products - (1) an isolate CBD oil and (2) a broad spectrum CBD oil - on self-ratings of effectiveness of the product and ability to manage stress.</p><p><strong>Methods: </strong>This quasi-experimental study reports on a total of 374 participants who completed either a 30- or 60-day regimen. Participants were instructed to use a 1,000 mg CBD isolate product at will, and then switch over to a 1,000 mg broad spectrum product for the remainder of the regimen (i.e., next 15 or 30 days). Self-reported effectiveness of the product and its ability to help manage stress was compared between the isolate and broad spectrum products. We also examined overall impression, quality, taste, and adverse effects of each product.</p><p><strong>Results: </strong>Overall, both products were rated to be highly effective and able to assist with stress management. Participants reported that the broad spectrum product's effectiveness (<i>p</i> < 0.001) and ability to reduce stress (<i>p</i> < 0.001) as greater than the isolate product across both regimens. However, participants preferred the taste of the isolate product over that of the broad spectrum across regimens (<i>p</i> < 0.05). For the 30-day regimen, participants reported a more positive overall impression of the isolate as compared to the broad spectrum (<i>p</i> < 0.001); however, overall impression did not differ between the products in the 60-day regimen. There was no difference in adverse effects or quality between the products, across both regimens.</p><p><strong>Conclusion: </strong>These results fit with prior studies suggesting anti-stress effects of CBD. Ratings were higher for the broad spectrum as compared to the isolate product, which is consistent with prior data suggesting that cannabinoids can work synergistically to maximize benefits. Nonetheless, more controlled studies are needed to explore these effects in nonclinical and clinical populations.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"6 1","pages":"138-147"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629851/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study.\",\"authors\":\"Mohammed Faraj, Tyler Dautrich, Leslie Lundahl, Hilary Marusak\",\"doi\":\"10.1159/000531886\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Estimated rates of past-month cannabidiol (CBD) use in the general public are 13-26% and emerging research examines CBD as a potential adjunct treatment for several medical conditions, including stress-related disorders (e.g., depression, anxiety, and chronic pain). However, little is known about the effects of different CBD products on self-reported stress. The present study compared the effects of two delta-9-tetrahydrocannabinol (THC)-free CBD tincture products - (1) an isolate CBD oil and (2) a broad spectrum CBD oil - on self-ratings of effectiveness of the product and ability to manage stress.</p><p><strong>Methods: </strong>This quasi-experimental study reports on a total of 374 participants who completed either a 30- or 60-day regimen. Participants were instructed to use a 1,000 mg CBD isolate product at will, and then switch over to a 1,000 mg broad spectrum product for the remainder of the regimen (i.e., next 15 or 30 days). Self-reported effectiveness of the product and its ability to help manage stress was compared between the isolate and broad spectrum products. We also examined overall impression, quality, taste, and adverse effects of each product.</p><p><strong>Results: </strong>Overall, both products were rated to be highly effective and able to assist with stress management. Participants reported that the broad spectrum product's effectiveness (<i>p</i> < 0.001) and ability to reduce stress (<i>p</i> < 0.001) as greater than the isolate product across both regimens. However, participants preferred the taste of the isolate product over that of the broad spectrum across regimens (<i>p</i> < 0.05). For the 30-day regimen, participants reported a more positive overall impression of the isolate as compared to the broad spectrum (<i>p</i> < 0.001); however, overall impression did not differ between the products in the 60-day regimen. There was no difference in adverse effects or quality between the products, across both regimens.</p><p><strong>Conclusion: </strong>These results fit with prior studies suggesting anti-stress effects of CBD. Ratings were higher for the broad spectrum as compared to the isolate product, which is consistent with prior data suggesting that cannabinoids can work synergistically to maximize benefits. Nonetheless, more controlled studies are needed to explore these effects in nonclinical and clinical populations.</p>\",\"PeriodicalId\":18415,\"journal\":{\"name\":\"Medical Cannabis and Cannabinoids\",\"volume\":\"6 1\",\"pages\":\"138-147\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629851/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Cannabis and Cannabinoids\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000531886\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000531886","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

引言:过去一个月,公众对大麻二酚(CBD)的使用率估计为13-26%,新兴研究将CBD作为几种疾病的潜在辅助治疗手段,包括压力相关疾病(如抑郁、焦虑和慢性疼痛)。然而,人们对不同CBD产品对自我报告压力的影响知之甚少。本研究比较了两种不含δ-9-四氢大麻酚(THC)的CBD酊剂产品——(1)一种分离的CBD油和(2)一种广谱CBD油——对产品有效性和管理压力能力的自我评级的影响。方法:这项准实验研究报告了总共374名参与者,他们完成了30天或60天的方案。参与者被指示随意使用1000 mg CBD分离产品,然后在该方案的剩余时间(即接下来的15或30天)改用1000 mg广谱产品。比较了隔离产品和广谱产品的自我报告有效性及其帮助管理压力的能力。我们还检查了每种产品的总体印象、质量、味道和不良影响。结果:总的来说,这两种产品都被评为非常有效,能够帮助压力管理。参与者报告称,在两种方案中,广谱产品的有效性(p<0.001)和减轻压力的能力(p<001)均高于分离产品。然而,在不同的治疗方案中,参与者更喜欢分离物产品的味道,而不是广谱的味道(p<0.05)。对于30天的治疗方案,参与者报告说,与广谱相比,分离物的总体印象更积极(p<0.001);然而,60天方案中的产品之间的总体印象没有差异。两种方案的不良反应或产品质量没有差异。结论:这些结果与先前的研究一致,表明CBD具有抗应激作用。与分离产品相比,广谱产品的评级更高,这与之前的数据一致,表明大麻素可以协同作用,最大限度地提高效益。尽管如此,还需要更多的对照研究来探索非临床和临床人群中的这些影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study.

Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study.

Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study.

Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study.

Introduction: Estimated rates of past-month cannabidiol (CBD) use in the general public are 13-26% and emerging research examines CBD as a potential adjunct treatment for several medical conditions, including stress-related disorders (e.g., depression, anxiety, and chronic pain). However, little is known about the effects of different CBD products on self-reported stress. The present study compared the effects of two delta-9-tetrahydrocannabinol (THC)-free CBD tincture products - (1) an isolate CBD oil and (2) a broad spectrum CBD oil - on self-ratings of effectiveness of the product and ability to manage stress.

Methods: This quasi-experimental study reports on a total of 374 participants who completed either a 30- or 60-day regimen. Participants were instructed to use a 1,000 mg CBD isolate product at will, and then switch over to a 1,000 mg broad spectrum product for the remainder of the regimen (i.e., next 15 or 30 days). Self-reported effectiveness of the product and its ability to help manage stress was compared between the isolate and broad spectrum products. We also examined overall impression, quality, taste, and adverse effects of each product.

Results: Overall, both products were rated to be highly effective and able to assist with stress management. Participants reported that the broad spectrum product's effectiveness (p < 0.001) and ability to reduce stress (p < 0.001) as greater than the isolate product across both regimens. However, participants preferred the taste of the isolate product over that of the broad spectrum across regimens (p < 0.05). For the 30-day regimen, participants reported a more positive overall impression of the isolate as compared to the broad spectrum (p < 0.001); however, overall impression did not differ between the products in the 60-day regimen. There was no difference in adverse effects or quality between the products, across both regimens.

Conclusion: These results fit with prior studies suggesting anti-stress effects of CBD. Ratings were higher for the broad spectrum as compared to the isolate product, which is consistent with prior data suggesting that cannabinoids can work synergistically to maximize benefits. Nonetheless, more controlled studies are needed to explore these effects in nonclinical and clinical populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信